Oxford Biomedica PLC Environmental Analytics
Environmental and financial analysis dashboard for Oxford Biomedica PLC. Industry: PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES
Company Overview for Oxford Biomedica PLC
Highlights
Showing data for FY2023
Operational Environmental Cost
$0.88m
Operational Environmental Cost Intensity
0.77%
Total Environmental Cost
$1.24m
Total Environmental Cost Intensity
1.09%
ΔOperational Environmental Cost (2020-2023)
$0.24m
Decoupling Rate (2020-2023)
-13%
Adjusted EBITDA
$-190m
Adjusted EBITDA Margin
-167%
Environmental cost statement
Showing data for FY2023
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 21.42% | -21.46% | -9.25% | ||
| 0.19% | 0.14% | 0.13% | 0.17% | |
| 12.35% | -14.80% | 71.11% | ||
| 0.35% | 0.24% | 0.24% | 0.60% | |
| $1m | $1m | $1m | $1m | |
| 15.53% | -17.25% | 43.01% | ||
| 0.54% | 0.38% | 0.37% | 0.77% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| 15.06% | 24.81% | -4.68% | ||
| 0.22% | 0.16% | 0.23% | 0.32% | |
| 15.39% | -5.00% | 24.75% | ||
| 0.76% | 0.54% | 0.59% | 1.09% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2023
Integrated financial analysis
Highlights
Showing data for FY2023
Adjusted EBITDA Margin
-167%
Adjusted EBIT Margin
-199%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2023
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$120m | $193m | $168m | $114m | |
| 61.28% | -12.94% | -32.22% | ||
$114m | $148m | $181m | $304m | |
| 95.24% | 76.73% | 107.76% | 265.98% | |
$6m | $45m | $-13m | $-189m | |
| 4.76% | 23.27% | -7.76% | -165.98% | |
$-8m | $28m | $-45m | $-226m | |
| -6.45% | 14.54% | -26.59% | -198.05% | |
| ENVIRONMENTAL COST DATA | ||||
$1m | $1m | $1m | $1m | |
| 0.54% | 0.38% | 0.37% | 0.77% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$5m | $44m | $-14m | $-190m | |
| 4.23% | 22.88% | -8.13% | -166.75% | |
$-8m | $27m | $-45m | $-227m | |
| -6.99% | 14.16% | -26.96% | -198.82% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2023
Industry benchmark
RESEARCH AND EXPERIMENTAL DEVELOPMENT ON NATURAL SCIENCES AND ENGINEERING
Scope 1 (% of Sales)
0.17%
Scope 2 (% of Sales)
0.60%
Operational Environmental Cost Intensity
0.77%
Scope 3 (% of Sales)
0.32%
Total Environmental Cost Intensity
1.09%
Selected peer group
Showing data for FY2023
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
Oxford Biomedica PLC | GB | $1m | 0.77% |
Loading similar companies data...
Industry distribution
Showing data for FY2023
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2023
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | $3m | 45.73% | N/A | N/A |
Energy-related activities (3) | $1m | 10.40% | N/A | N/A |
Upstream transportation (4) | $1m | 10.65% | N/A | N/A |
Waste (5) | $0m | 1.24% | N/A | N/A |
Business travel (6) | $0m | 0.77% | N/A | N/A |
Commuting (7) | $0m | 0.71% | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | $1m | 9.14% | N/A | N/A |
Processing of products (10) | $0m | 0.03% | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | $1m | 21.34% | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $6m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2023